Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
GSK plc brands
Fluticasone furoate
Другие языки:

    Fluticasone furoate

    Подписчиков: 0, рейтинг: 0
    For other uses, see Fluticasone.

    Fluticasone furoate
    Fluticasone furoate.svg
    Clinical data
    Trade names Flonase Sensimist, Veramyst, others
    AHFS/Drugs.com Monograph
    License data
    Pregnancy
    category
    • AU: B3
    Routes of
    administration    		 Intranasal, by mouth
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • UK: POM (Prescription only)
    • US: / Rx-only
    • EU: Rx-only
    Pharmacokinetic data
    Bioavailability 0.51% (Intranasal)
    Protein binding 91%
    Metabolism Intranasal
    Liver (CYP3A4-mediated)
    Elimination half-life 15 hours
    Excretion Kidney
    Identifiers
    • (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.158.130
    Chemical and physical data
    Formula C27H29F3O6S
    Molar mass 538.58 g·mol−1
    3D model (JSmol)
    • CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
    • InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
    • Key:XTULMSXFIHGYFS-VLSRWLAYSA-N

    Fluticasone furoate, sold under the brand name Flonase Sensimist and formerlyVeramyst, among others, is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray. It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol. Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.

    It was approved for medical use in the United States in April 2007, and in the European Union in November 2008. In 2020, fluticasone was the 23rd most commonly prescribed medication in the United States, with more than 24 million prescriptions.

    Society and culture

    Brand names

    In the US it is marketed by GlaxoSmithKline for asthma as Arnuity Ellipta and is only available with a prescription. It is marketed over-the-counter for allergic rhinitis as Flonase Sensimist. The Veramyst brand name has been discontinued in the US. It is also marketed as Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, Italy, India, Taiwan and South Korea).

    The combination drugs fluticasone furoate/umeclidinium bromide/vilanterol, marketed as Trelegy Ellipta, and fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada, New Zealand) and Relvar Ellipta (EU, UK), are approved for use in the United States for long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD). They are also approved for the treatment of asthma.


    See also

    External links



    Новое сообщение